SCHEMBL2154186

SCHEMBL2154186

CC(C(N)=O)c1c[nH]cn1

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1218467 0.82 PTGS2 (0.33)
Hydrochloric Acid SCHEMBL1375002 0.81 POLB (0.33)
Hydrochloric Acid SCHEMBL6625509 0.81 POLB (0.33)
Hydrochloric Acid SCHEMBL9098535 0.79
SCHEMBL2477673 0.78 PTGS1 (0.33)
SCHEMBL7433283 0.77
SCHEMBL3464436 0.77 GAA (0.30)
SCHEMBL28648377 0.76
Hydrochloric Acid SCHEMBL9231395 0.76
Hydrochloric Acid SCHEMBL29212222 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023207875-A1 CDK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) 2023-11-02 WO claimed
EP-2342194-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2011-07-13 EP claimed
WO-2023207875-A1 CDK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) 2023-11-02 WO disclosed
EP-2970321-A2 BUPRENORPHINE ANALOGS Purdue Pharma LP (US) 2016-01-20 EP disclosed
WO-2014140784-A2 BUPRENORPHINE ANALOGS PURDUE PHARMA L.P. (US) 2014-09-18 WO disclosed
EP-2726478-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2014-05-07 EP disclosed
EP-2655330-A1 SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS Purdue Pharma LP (US) 2013-10-30 EP disclosed
WO-2013001030-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-01-03 WO disclosed
WO-2012085650-A1 SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA L.P. (US) 2012-06-28 WO disclosed
EP-2342194-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2011-07-13 EP disclosed